Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, July 1998, p. 574-577, Vol. 5, No. 4
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Comparison of Inflammatory Events during Developing
Immunoglobulin E-Mediated Late-Phase Reactions and
Delayed-Hypersensitivity Reactions
Burton
Zweiman,*
Anne
R.
Moskovitz, and
Carolyn
von Allmen
Allergy and Immunology Division, Department
of Medicine, University of Pennsylvania Medical Center,
Philadelphia, Pennsylvania
Received 15 December 1997/Returned for modification 9 February
1998/Accepted 3 April 1998
 |
ABSTRACT |
To compare cellular and mediator responses in early developing
late-phase skin reactions (LPR) and delayed-hypersensitivity (DH)
reactions in the same subjects, responses in skin chambers overlying
sites of challenge with pollen antigen and Candida albicans antigens were compared in six humans with demonstrated prominent LPR
and DH responses. Histamine levels in overlying chamber fluids at
1 h were much higher at LPR than at DH sites (P = 0.002). After the next 4 h, leukocyte exudation was higher at LPR
than at DH sites (P = 0.005). Most leukocytes were
activated neutrophils with greater frequency of superoxide-secreting
cells and released lactoferrin at LPR than at DH sites
(P = 0.01 and P = 0.02, respectively). The frequency of exuding eosinophils was
higher, but not significantly so (P = 0.5), at LPR
sites. Although significantly more eosinophils at LPR sites were
activated (P = 0.02), the levels of released eosinophilic cationic protein were not significantly higher at LPR
sites (P = 0.09). The levels of interleukin-8 (IL-8),
but not IL-6, were greater at LPR than at DH sites. During the first 5 h of challenge there was greater mast cell activation and
subsequent exudation of activated neutrophils at sites of developing
LPR than at DH sites, possibly related to greater local IL-8 levels. The frequency of activated eosinophils was also greater at LPR sites.
These different initial inflammatory responses could play a role in determining expression of LPR or DH reactions.
 |
INTRODUCTION |
Both late-phase immunoglobulin
E-mediated reactions (LPR) and delayed-hypersensitivity (DH)
responses to microbial antigens in the skin are characterized by
erythematous, indurated reactions (1, 8, 22). Findings in
sequential biopsy samples suggest that T lymphocytes play a pathogenic
role in LPR as well as DH reactions (4, 5, 19). However, it
is felt that different pathogenic mechanisms underlie LPR and DH
responses. There may be different profiles of T-cell subpopulations in
established LPR and DH (5, 15). Granulocyte accumulation is
seen in biopsy samples obtained during the first hours after challenge
in both LPR and DH (1, 19). However, there is a more
prominent accumulation of eosinophils in LPR (4, 19).
We have focused our previous investigations on the inflammatory events
occurring during the first 5 to 6 h after intradermal challenge
with antigen leading to grossly well-expressed LPR by the sixth hour.
Using a skin chamber model, we have noted the accumulation, by the
sixth hour, of neutrophils and eosinophils, release of their granular
proteins, and increased local levels of several proinflammatory
mediators, including cytokines (12, 14, 20, 21, 24).
It is felt by several investigators of DH reactivity that expression of
this immune response is actually initiated in the first several hours
after intradermal antigen challenge, even though the DH reaction may
not be grossly apparent until at least 12 h later (reviewed in
references 1 and 22). Because
local accumulation of granulocytes is found in biopsy specimens
obtained in the first several hours after intradermal antigen injection leading to both LPR and DH reactions, it is important to compare the
profiles of inflammatory events occurring during these early hours
after antigen challenge which may determine the subsequent gross
expression of LPR or DH in the skin. We have used our skin chamber
approach to make such comparisons for human subjects manifesting both
types of responses.
 |
MATERIALS AND METHODS |
Subjects and skin testing.
In screening studies, we
identified six human volunteers, healthy except for seasonal allergic
rhinitis, who manifested similarly sized erythematous, indurated
reactions 24 h following intradermal injection of both grass or
ragweed pollen extract (100 protein nitrogen units [PNU]/ml;
Greer Labs, Lenoir, N.C.) (induration diameter, 9 ± 2 mm)
(mean ± standard error of the mean) and Candida albicans extract (500 PNU/ml; Greer Labs) (induration diameter, 12 ± 3 mm). There were minimal reactions (
1-mm
diameter) at 24 h to intradermal injection with the buffered
solution used to dilute these extracts. No subject was receiving
medication at the time of the study.
Skin chamber studies.
Skin chamber studies were performed
outside the relevant pollenating season as previously described
(12). In brief, four blisters were induced on the volar
surfaces of the forearms by gentle heat and suction. The epidermal
blister roofs were removed from the blister bases at the
dermal-epidermal junction, and collection chambers were appended. After
irrigation of each blister base with buffer diluent (phosphate-buffered
saline [PBS]) twice for 5 min time, 0.3 ml of grass or ragweed pollen
antigens (Greer Labs) diluted to 100 PNU/ml in PBS containing heparin
at 10 U/ml (PAg) was placed in the chambers at one site.
Candida extract (500 PNU/ml) diluted in the same PBS-heparin
solution was placed in chambers at two additional sites. As a control,
the PBS diluent containing heparin at 10 U/ml (solution B) was placed
in the chambers at the fourth site. All solutions had been shown to be
endotoxin free by the Limulus test. After 1 h, the
fluids were removed, and the fluids from duplicate chambers were
pooled. They were then assayed for histamine levels with an
enzyme-linked immunosorbent assay (ELISA) (Immunotech, Westbrook,
Maine) sensitive to 0.1 ng/ml.
The chamber bases were then irrigated with PBS, and 0.3 ml of fresh
PAg. Candida solution, or solution B (all containing heparin at 10 U/ml) was placed in each of the chambers previously containing like solutions and allowed to remain for an additional 4 h. Fluids from the four challenge chambers were removed, fluids from the duplicate sites of Candida challenge were pooled, and the
total cell counts in the fluids at the PAg, Candida, and
solution B challenge sites were assessed. These fluids were then
centrifuged, and the supernatants were analyzed for levels of
histamine, eosinophilic cationic protein (ECP) (measured with a
radioimmunoassay [Pharmacia, Piscataway, N.J.] sensitive to 2 ng/ml),
lactoferrin (measured with an ELISA sensitive to 2 µg/ml, as
described by us [20]), interleukin-6 (IL-6) (measured
with an ELISA [R&D, Minneapolis, Minn.] sensitive to 3.1 pg/ml), and
IL-8 (measured with an ELISA [R&D] sensitive to 31 pg/ml). The cell
pellets were resuspended in PBS-heparin. Aliquots were either counted
for total cells (with a Coulter Counter [Coulter, Hialeah, Fla.]),
cytocentrifuged (apparatus from Shandon) for subsequent differential
counting by Wright's staining (Dif-Quik), or cytocentrifuged and
studied by immunocytochemical approaches to determine the percentage of
cells binding the EG2 antibody (Pharmacia) as described by
us (23).
Immediately after removal of the skin chambers and the fluid contained
therein, 10-mm-diameter sterile cover glasses were
appended firmly to
the blister bases for 15 min to obtain the
cell imprints. The cover
glasses were then removed and, while
still moist, were
immediately placed in 25-mm-diameter wells of
a tissue culture
plate containing a solution of nitroblue tetrazolium
(NBT) (N
5514; Sigma, St. Louis, Mo.). After a 30-min incubation
at 37°C in a
CO
2 incubator, the NBT solution was aspirated, and
the cover glasses were left for 1 min at room temperature to
evaporate
any residual fluid. Absolute methanol was added for 5 min for
fixation and then aspirated, and the cover glasses were counterstained
with 1% safranin to determine the total number of cells counted.
Stained cover glasses were mounted faceup on coded microscope
slides,
and a fresh cover glass was appended to each with Permount.
In each
imprint the percentage of safranin-stained cells which
showed prominent
deposition of the formazan metabolite (>3 grains/cell)
due to
superoxide activity (
17) was determined.
Superoxide-secreting
granulocytes are considered activated since
resting granulocytes
rarely secrete superoxide prominently
(
17).
To help ascertain the significance of cells producing superoxide in
populations of cells exuding at the various challenge
sites, the
frequency of NBT
+ cells in these populations was compared
with that in autologous
blood leukocytes. Blood specimens were
collected into heparin-containing
tubes from all subjects just prior to
induction of the skin blister
on the day of the experiment. A
predominantly granulocyte (>90%)
subpopulation of the blood
leukocytes was obtained by density
gradient centrifugation, as utilized
previously by us (
10).
Aliquots of these cells were
suspended in the NBT solution described
above (10
6
cells/ml) either alone or with added agonists (tumor necrosis
factor
alpha [5 U/ml; R&D Labs] and phorbol myristic acetate [10
ng/ml; P
8139; Sigma]). After incubation at 37°C for 30 min in
a
CO
2 incubator, the cells were cytocentrifuged, fixed in
methanol,
counterstained with safranin, and mounted in Permount, as
described
above.
Statistical analyses.
Cell counts and levels of cytokines
and inflammatory mediators in the skin chamber fluids at the PAg,
Candida, and solution B sites in the same individuals were
compared by paired Student's t test when the data were
normally distributed and by Wilcoxon's rank sum test when
nonparametric statistics were required. Associations between different
inflammatory responses in the same chamber fluids were investigated by
Spearman's rank correlation analysis.
 |
RESULTS |
Histamine levels after the first hour of challenge.
The
histamine levels were much higher at the PAg sites (69 ± 10 ng/ml) than at the Candida sites (2 ± 1 ng/ml).
The level at the latter sites was not significantly different from that at the solution B (control) challenge sites (2 ± 2 ng/ml).
Inflammatory events during the second to fifth hours of
challenge.
The number of cells exuding from the PAg challenge
sites into the overlying skin chamber fluid (6.1 × 105 cells) was significantly greater than the very low
number of cells in the pooled chamber fluids from the two
Candida challenge sites (0.6 × 105
cells/site) (P = 0.005) (Table
1). Indeed, we had set up a protocol to
pool fluids from duplicate Candida challenge sites to get
reliable cell counts in case the number of cells exuding from an
individual Candida site was very low. If anything, the
frequency of cells exuding at these sites was somewhat lower than that
at solution B (control) challenge sites (Table 1).
The large majority of the exuding cells were neutrophils. The relative
frequency of eosinophils in the cells at both the PAg
and
Candida sites was quite variable from subject to subject,
and it was not correlated significantly with the percentage of
eosinophils in the blood of individual subjects. Therefore, the
mean
frequency of eosinophils in fluids from the PAg sites (19%
± 9%) was
higher than that in fluids from the
Candida sites (12%
± 5%), but not significantly so (
P = 0.5). The frequency
of eosinophils
in the solution B challenge sites was significantly
lower than
that at either the PAg or
Candida challenge sites
(4% ± 2%) (
P 
0.01). There were very few (<5%)
lymphocytes in the chamber
fluids obtained at the PAg or
Candida challenge sites. We have
consistently found few
lymphocytes in chamber fluids obtained
after 6 h of PAg challenge.
Many of the neutrophils exuding in greater numbers at PAg than at
Candida challenge sites were activated, so the levels of
lactoferrin, released from the specific granules of neutrophils,
were
higher at PAg sites (13.2 ± 3.7 µg/ml) than at
Candida challenge
sites (3.8 ± 1.6 µg/ml)
(
P = 0.02) (Table
2). The
levels at the
latter sites were not significantly different from those
at the
solution B challenge sites (3.0 ± 2.0 µg/ml).
Also, the frequency of cells which were strongly NBT
+,
presumably due to secreted superoxide (
17), was
significantly higher
at the PAg sites (60% ± 11%) than at the
Candida challenge sites
(25% ± 6%) (
P = 0.01). The responses at both these sites were
significantly greater
than that in cells exuding at the solution
B challenge sites (9% ± 5%) (
P 
0.01) (Table
1). The mean frequency
of
strongly NBT
+ cells in the exudate at the PAg challenge
sites (60%) approached
that (87% ± 8%) seen in autologous blood
granulocytes which were
obtained just prior to the skin chamber study
and then stimulated
in vitro by phorbol myristic acetate, a potent
neutrophil activator.
Very few of these autologous blood neutrophils
were NBT
+ when incubated without agonists (1% ± 1%).
Although the frequency of eosinophils in the exudate at the PAg
challenge sites was only modestly greater than at the
Candida sites, the majority of these eosinophils appeared to
be activated,
as indicated by the frequency of
EG
2+ cells at the PAg sites (12.5% ± 3%),
which was significantly
greater than the frequency of
EG
2+ cells at the
Candida sites (2% ± 1%) (
P = 0.02) (Table
1). However,
the skin chamber
levels of ECP, released from activated eosinophils,
varied considerably
among subjects. Therefore, the mean ECP level
in fluid at PAg sites
(71 ± 23 ng/ml) was higher than that at
Candida sites
(26 ± 12 ng/ml), but not significantly so (
P = 0.09)
(Table
2). The mean ECP level at the
Candida sites was
not much
higher than that seen at the solution B (control) sites
(18 ±
5 ng/ml).
Cytokine levels after the second to fifth hours of challenge.
The mean IL-6 levels at the PAg, Candida, and solution B
challenge sites were quite similar (3,051 ± 632, 3,086 ± 1,178, and 4,046 ± 1,435 pg/ml, respectively), but with
considerable variation in levels among the six subjects (Table 2). This
lack of a significant difference between the IL-6 levels at the PAg and
solution B challenge sites confirmed findings in other subjects
recently reported by members of our group (24) but was
different than the increased levels in PAg site chamber fluids reported
previously by another group (7).
The skin chamber IL-8 levels after 2 to 5 h were significantly
higher at sites of PAg challenge than at solution B challenge
sites
(5,871 ± 1,564 and 1,242 ± 387 pg/ml, respectively
(
P =
0.02) (Table
2). This finding confirmed earlier
observations
by members of our group (
24). The IL-8 level at
Candida challenge
sites (1,578 ± 797 pg/ml) was
significantly less than that at
PAg challenge sites (
P = 0.04) (Table
2). However, there was
marked variation in IL-8 levels
at
Candida challenge sites among
the study subjects, with
the mean value not significantly higher
than the levels seen at the
control (solution B) challenge sites
(
P = 0.7). The
levels of IL-8 correlated significantly with the
levels of lactoferrin
in the PAg site fluids of individual subjects
(
P < 0.05), confirming earlier observations by members of our
group
(
24). However, there was no significant correlation between
the IL-8 levels and neutrophil numbers in chamber fluids at individual
sites.
 |
DISCUSSION |
The prominent LPR seen in the skin of some subjects following
strong immediate immunoglobulin E-mediated reactions is often similar
in gross appearance to the classic DH reactions to microbial antigens
at 24 h. However, there are some differences between the patterns
of gross inflammation in those two types of responses: (i) a prominent
wheal-and-flare reaction at 20 to 30 min almost always precedes LPR but
is very unusual before the onset of a true DH reaction (1);
(ii) the LPR often starts as a continuation of the edematous reaction
within 2 to 3 h of intradermal challenge, whereas gross
inflammation is generally not apparent at DH reaction sites until at
least 6 h, when LPR are generally already well developed (1,
23); and (iii) in our experience, gross LPR frequently begin to
wane by 24 h and are present at 48 to 72 h in less than 50%
of individuals with earlier LPR. In contrast, prominent DH reactions
are grossly apparent for at least 48 h after challenge (1,
22).
The histologic patterns of LPR and DH seen in sequential biopsy samples
also differ somewhat. Neutrophils frequently accumulate within several
hours after challenge in both LPR and DH. Eosinophils are more
prominent at LPR sites, while monocytes/macrophages are prominent at
later periods in DH but not LPR. Mast cells are now thought to play
important roles in the initiation of DH reactions as well as LPR
(1, 8). Basophils are likely recruited into the sites of
both DH and LPR (1, 3) and may be the source of the
prolonged local histamine release seen in the latter (11).
Perhaps the most impressive histologic difference between LPR and DH
responses involves T lymphocytes. Several groups have reported a
significant increase in T-cell numbers in biopsy samples obtained from
LPR sites 6 h after intradermal antigen challenge, persisting for
up to 96 h (4, 5, 15). In situ hybridization studies
suggested that these cells were of the TH-2 type, containing mRNA for
IL-3, IL-5, and granulocyte-macrophage colony-stimulating factor
(15). In contrast, T lymphocytes accumulated later (at 24 to
48 h) at sites of DH reactions, with predominantly mRNA for gamma
interferon and IL-2 found by in situ hybridization (15). We
have found a more variable pattern of T-lymphocyte accumulation at LPR
sites at 6 h, with impressively greater numbers of T cells in
antigen challenge sites than in buffer-treated control sites in some,
but not all, subjects (23). In some individuals, there was a
more prominent increase in the frequency of T cells at 24 h than
at 6 h. We have found increased levels of mRNA for IL-5 by reverse
transcriptase PCR at 6 and 24 h at LPR sites, but not at DH sites
(9, 16). Therefore, further clarification of the mechanisms
underlying LPR and DH responses was needed.
In the present study, we did find several significantly different
responses occurring during the initiation of LPR and DH reactions.
First, there was evidence of immediate mast cell activation leading to
prominent histamine release at sites of developing LPR but not at sites
of developing DH reactions. Such histamine release could be accompanied
by secretion of other mast cell components that directly or indirectly
lead to inflammatory LPR.
In the present study, we also found significantly greater neutrophil
exudation into the skin chambers overlying sites of developing LPR than
in those overlying sites of developing DH reactions during the first
5 h of challenge. Many of the neutrophils accumulating in greater
numbers in fluids overlying sites of developing LPR were activated,
secreting superoxide and releasing lactoferrin, a granular protein. The
stimulus for this neutrophil response in LPR has not yet been defined.
We have previously found agents released into skin chamber fluid early
during PAg challenge, such as leukotriene B4, which will
attract and/or activate neutrophils in vitro (10). There has
been considerable interest in the possible roles of cytokines in skin
inflammatory reactions (6). Lee et al. reported increased
levels of IL-6 in the fluids of skin chambers overlying sites of
developing LPR in a temporally biphasic pattern (7). In the
present study, we found no difference in IL-6 levels at LPR and
control sites. Members of our group have also found increased
levels of several chemokines, including IL-8 and
regulated-upon-activation, normal-T-cell-expressed and -secreted chemokine (RANTES), in chamber fluids overlying sites of
developing LPR (24). Significantly greater IL-8 levels were
found in chamber fluids at the sites of developing LPR than at the
sites of developing DH reactions in the study reported here. IL-8
levels correlated with lactoferrin levels in the LPR site fluids,
supporting the concept that IL-8 played a major role in the activation
of neutrophils found at LPR sites. IL-8 is a potent neutrophil
chemoattractant and activator and can be released by other cells at
such reaction sites (13). There were very few lymphocytes
present in the chamber fluid as a possible source of IL-8 or another
neutrophil chemoattractant. However, it is conceivable that IL-8 could
be released from lymphocytes in the underlying dermis or from
keratinocytes in the surrounding epidermis.
Somewhat surprisingly, there was not a significantly greater exudation
of eosinophils into the chambers at the LPR than at the DH sites,
although the frequency of EG2+ (putatively
activated) eosinophils was significantly higher in the LPR site
exudates. However, the release of ECP, a cationic granule protein of
eosinophils, was quite variable at both LPR and DH sites, resulting in
a nonsignificant difference in mean ECP levels in these two response
patterns. The ECP levels in the PAg site fluids, but not in the
Candida site fluids, were significantly greater than at the
solution B-treated (control) sites. A small percentage of the ECP found
at both PAg and Candida sites could be derived from that
present in the modest exudate containing plasma proteins released into
the overlying skin chambers during the first 5 h of PAg and
Candida challenge (2). However, previous immunofluorescence studies have shown marked deposition of eosinophil granule proteins in the dermis during the first 5 h of PAg
challenge (21).
Members of our group have previously found elevated levels of RANTES in
fluids from chambers overlying PAg challenge sites (24).
RANTES is a potent attractant and activator of eosinophils (18). Unfortunately, there were insufficient amounts of
chamber fluid available to compare RANTES levels at PAg and
Candida challenge sites in the present study. mRNA for IL-5,
a cytokine which can activate and prolong survival of eosinophils, has
been found at LPR sites (15, 16). It has also been found
that such IL-5 mRNA deposition correlates with the modest percentage of
cells containing IL-5 protein (9). However, we have not
found IL-5 protein released into the overlying chamber fluids at PAg
challenge sites, possibly because of inadequately sensitive techniques.
Thus, it appears that LPR and DH reactions, which may appear grossly
similar at 24 h after intradermal challenge, are characterized by
different patterns of mast cell activation and granulocyte response
during the first 5 h of challenge. The greater neutrophil responses at sites of developing LPR may be due to the higher local
IL-8 levels at such sites. Further characterization of the causal
inflammatory mediators may enhance our understanding of pathogenic
mechanisms in these two types of immune responses.
 |
ACKNOWLEDGMENT |
This work was supported by NIH grant RO1 AI 14332.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: University of
Pennsylvania School of Medicine, 512 Johnson Pavilion, Philadelphia, PA
19104-6057. Phone: (215) 898-6525. Fax: (215) 349-5919.
 |
REFERENCES |
| 1.
|
Askenase, P. W.
1993.
Effector and regulatory mechanisms in delayed-type hypersensitivity, p. 362-389.
In
E. E. Middleton, Jr., C. E. Reed, E. E. Ellis, N. F. Adkinson, Jr., and J. W. Yunginger (ed.), Allergy: principles and practice. C. V. Mosby, St. Louis, Mo.
|
| 2.
|
Atkins, P. C.,
A. P. Kaplan,
C. von Allmen,
A. R. Moskovitz, and B. Zweiman.
1992.
Activation of the coagulation pathway during ongoing allergic cutaneous reactions in humans.
J. Allergy Clin. Immunol.
89:552-559[Medline].
|
| 3.
|
Charlesworth, E. N.,
A. F. Hood,
N. A. Soter,
A. Kagey-Sobotka,
P. S. Norman, and L. M. Lichtenstein.
1989.
Cutaneous late-phase response to allergen. Mediator release and inflammatory cell infiltration.
J. Clin. Invest.
83:1519-1526.
|
| 4.
|
Frew, A. J., and A. B. Kay.
1988.
The relationship between CD4+ lymphocytes, activated eosinophils and the magnitude of the allergen-induced late phase skin reaction in man.
J. Immunol.
141:4158-4164[Abstract].
|
| 5.
|
Gaga, M.,
A. J. Frew,
V. Varney, and A. B. Kay.
1991.
Eosinophil activation and T lymphocyte infiltration in allergen-induced late phase reactions and classical delayed-type hypersensitivity in man.
J. Immunol.
147:816-822[Abstract].
|
| 6.
|
Kaplan, A. P.,
P. Kuna, and S. R. Reddigari.
1994.
Chemokines as allergic mediators: relationship to histamine-releasing factors.
Allergy
49:495-501[Medline].
|
| 7.
|
Lee, C. E.,
M. W. Newland,
H. G. Teaford,
B. F. Villacis,
P. S. Dixon,
S. Valtheer, et al.
1992.
Interleukin-6 is released with the cutaneous response to allergen challenge in atopic individuals.
J. Allergy Clin. Immunol.
89:1010-1020[Medline].
|
| 8.
|
Lemanske, R. F., Jr., and M. A. Kaliner.
1993.
Late phase allergic reactions, p. 320-361.
In
E. E. Middleton, Jr., C. E. Reed, E. E. Ellis, N. F. Adkinson, Jr., and J. W. Yunginger (ed.), Allergy: principles and practice. C. V. Mosby, St. Louis, Mo.
|
| 9.
|
Parrott, C. M.,
Y. Graif,
S. R. Lessin, and B. Zweiman.
1997.
Quantitative analysis of cytokines in cutaneous late phase (LPR) allergic reactions: a role for IL-5 in the developing LPR.
J. Allergy Clin. Immunol.
99:S170.
|
| 10.
|
Sato, K.,
B. Zweiman,
A. R. Moskovitz,
C. von Allmen, and P. C. Atkins.
1992.
Neutrophil activation by skin chamber fluids from allergic reaction sites.
J. Allergy Clin. Immunol.
90:21-31[Medline].
|
| 11.
|
Shalit, M.,
L. B. Schwartz,
N. Golzar,
C. von Allmen,
M. Valenzano,
P. Fleekop,
P. C. Atkins, and B. Zweiman.
1988.
Release of histamine and tryptase in vivo after prolonged cutaneous challenge with allergen in humans.
J. Immunol.
141:821-826[Abstract].
|
| 12.
|
Shalit, M.,
F. H. Valone,
P. C. Atkins,
W. D. Ratnoff,
E. J. Goetzl, and B. Zweiman.
1989.
Late appearance of phospholipid platelet activating factor and leukotriene D4 in human skin after repeated antigen challenge.
J. Allergy Clin. Immunol.
83:691-696[Medline].
|
| 13.
|
Swensson, O.,
C. Schubert,
E. Christopher, and J. M. Schroder.
1991.
Inflammatory properties of NPA-1/IL-8 in human skin.
J. Investig. Dermatol.
96:862-869.
|
| 14.
|
Talbot, S. F.,
P. C. Atkins,
E. J. Goetzl, and B. Zweiman.
1985.
Accumulation of leukotriene C4 and histamine in human allergic skin reactions.
J. Clin. Invest.
76:650-656.
|
| 15.
|
Tsicopoulos, A.,
Q. Hamid,
A. Haczku,
M. R. Jacobson,
S. R. Durham,
J. North, et al.
1994.
Kinetics of cell infiltration and cytokine messenger RNA expression after intradermal challenge with allergen and tuberculin in the same atopic individuals.
J. Allergy Clin. Immunol.
94:764-772[Medline].
|
| 16.
|
Vowels, B. R.,
A. L. Rook,
M. Cassin, and B. Zweiman.
1995.
Expression of IL-4 and IL-5 mRNA in developing cutaneous late phase reactions.
J. Allergy Clin. Immunol.
96:92-96[Medline].
|
| 17.
|
Weber, G. F.
1990.
The measurement of oxygen-derived free radicals and related substances in medicine.
J. Clin. Chem. Clin. Biochem.
28:569-603[Medline].
|
| 18.
|
Zhang, L.,
A. E. Redington, and S. T. Holgate.
1994.
RANTES: a novel mediator of allergic inflammation.
Clin. Exp. Allergy
24:899-904[Medline].
|
| 19.
|
Zweiman, B.
1988.
Mediators of allergic inflammation in the skin.
Clin. Allergy
18:847.
|
| 20.
|
Zweiman, B.,
U. Kucich,
M. Shalit,
C. von Allmen,
A. R. Moskovitz,
G. Weinbaum, and P. C. Atkins.
1990.
Release of lactoferrin and elastase in human allergic skin reactions.
J. Immunol.
144:3953-3960[Abstract].
|
| 21.
|
Zweiman, B.,
P. C. Atkins,
C. von Allmen, and G. J. Gleich.
1991.
Release of eosinophil granule proteins during IgE-mediated allergic skin reactions.
J. Allergy Clin. Immunol.
87:984-891[Medline].
|
| 22.
|
Zweiman, B., and A. I. Levinson.
1993.
Cell-mediated immunity, p. 963-968.
In
E. E. Middleton, Jr., C. E. Reed, E. E. Ellis, N. F. Adkinson, Jr., and J. W. Yunginger (ed.), Allergy: principles and practice. C. V. Mosby, St. Louis, Mo.
|
| 23.
|
Zweiman, B.,
P. C. Atkins,
A. R. Moskovitz,
C. von Allmen, and M. Ciliberti.
1997.
Cellular inflammatory responses during immediate developing and established late phase cutaneous reactions: effects of cetirizine.
J. Allergy Clin. Immunol.
99:801-811.
|
| 24.
|
Zweiman, B.,
A. P. Kaplan,
K. Joseph, and A. R. Moskovitz.
1997.
Cytokine levels and inflammatory responses in developing allergic late phase reactions in the skin.
J. Allergy Clin. Immunol.
100:104-109[Medline].
|
Clinical and Diagnostic Laboratory Immunology, July 1998, p. 574-577, Vol. 5, No. 4
1071-412X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.